Menlo Park, California-based Orca Bio closed on a Series D financing worth $192 million, bringing the total raised since 2016 to $300 million.

Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures and Atlas Venture with $48.5 million in Series A financing.

Cambridge, Massachusetts-based Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma GmbH to improve curative bone marrow transplantation.